Subscribe to NRx Newsletter
NIH ACTIV-3b Tesico Trial


ZYESAMI® NIH Tesico Trial

Zyesami® is a formulation of aviptadil acetate produced by NRx Pharmaceuticals.

It is actively enrolled in clinical trials under ACTIV-3b: TESICO (Therapeutics For Severely Ill Inpatients With Covid-19).  This clinical trial is for hospitalized patients who are experiencing Acute Respiratory Distress Syndrome (ARDS), a life-threatening condition in which the lungs are severely inflamed and may be unable to maintain sufficient oxygen in the blood.

For more information on this clinical trial under ACTIV-3b TESICO and criteria for joining this study, click here.